Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Imcyse, Pfizer Enter Imotope Research Pact | Contract Pharma

What are you searching for?

Sign in
Collaborations & Alliances

Imcyse, Pfizer Enter Imotope Research Pact

Aims to develop an Imotope targeting rheumatoid arthritis

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Imcyse SA, a biotechnology company developing active specific therapies for the treatment of severe chronic diseases, has entered into a research collaboration with Pfizer to develop an Imotope, a specific modified peptide, targeting rheumatoid arthritis (RA).
 
Pfizer will provide undisclosed funding for research and has an exclusive option to negotiate a license agreement following the research activities. Also, Pfizer will perform preclinical evaluation of another of Imcyse’s Imotopes targeting multiple sclerosis (MS) to better understand the mode of action of Imcyse’s Imotope technology platform. Imcyse will have access to select technology platforms at Pfizer as well as all research results related to this collaboration.
 
“We are pleased to announce this collaboration with Pfizer, as it further demonstrates the potential of our Imotope technology and its potential application to pharmaceutical research,” said Pierre Vandepapelière, chief executive officer of Imcyse. “The collaboration with Pfizer in these two fields of application will help us confirm the potential for our technology in others.” 
 

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics